Looking into this to treat the remaining problems that medication won't fix but CBD is expensive.
https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1386263/full
Quote: However, individuals with schizophrenia commonly use cannabis and cannabis derivatives such as cannabidiol (CBD). These products seem to alleviate psychotic symptoms and relieve adverse side effects of antipsychotic medications. Therefore, one notion that has gained traction is the potential utility of cannabis-derived cannabidiol (CBD) as adjunct treatment to reduce schizophrenia-associated psychosis and other symptoms. Currently, preclinical and clinical data remain inconclusive.
AI's awnser... In clinical trials evaluating cannabidiol (CBD) for schizophrenia and psychosis, researchers have generally used much higher doses than what is typically found in over-the-counter wellness products. The doses tested in major clinical trials typically range from **600 mg to 1,500 mg per day**, administered orally. The specific dosages used across the most notable clinical trials break down as follows: ### 1,000 mg/day (The Most Commonly Studied Adjunctive Dose) This is widely considered the standard dose for testing CBD as an add-on treatment to traditional antipsychotics. * **The McGuire et al. Trial (2018):** In a prominent multicenter randomized controlled trial (RCT), 88 outpatients with schizophrenia received either **1,000 mg/day** of an oral CBD solution (divided into two daily doses) or a placebo for 6 weeks alongside their existing antipsychotic medication. The study noted a modest but significant reduction in positive psychotic symptoms (such as delusions and hallucinations) and good tolerability. ### 800 mg/day (The Monotherapy Dose) This dosage has been used to evaluate CBD as a standalone treatment compared directly against standard antipsychotic drugs. * **The Leweke et al. Trial (2012):** In a pioneering double-blind RCT, 42 hospitalized patients with acute paranoid schizophrenia were randomized to receive either **800 mg/day** of oral CBD or a standard dose of the potent antipsychotic *amisulpride* for 4 weeks. The study found that 800 mg of CBD was similarly effective to amisulpride in reducing psychotic symptoms and improving cognition, but it produced significantly fewer side effects (such as weight gain or movement disorders). ### 600 mg/day (Mixed and Preventive Results) Lower continuous doses have yielded mixed results in chronic populations but show promise for early-stage intervention. * **Chronic Schizophrenia:** A 2018 study by Boggs et al. evaluated **600 mg/day** of oral CBD as an add-on therapy for 36 stable patients with chronic schizophrenia over 6 weeks. This trial found no significant difference between the CBD and placebo groups regarding symptom reduction or cognitive performance. * **Clinical High Risk / Early Psychosis:** McGuire and colleagues also utilized a single daily dose of **600 mg** in a short-term trial (21 days) with antipsychotic-naive individuals at a high clinical risk for developing psychosis. Neuroimaging showed that a 600 mg dose helped normalize abnormal brain function in areas like the striatum, midbrain, and hippocampus. ### 1,200 mg to 1,500 mg/day (High-Dose / Case Studies) * **Treatment-Resistant Populations:** In early exploratory open-label trials and case reports (such as those by Zuardi et al.), researchers titrated patients with severe or treatment-resistant schizophrenia up to **1,280 mg/day** or **1,500 mg/day**. While well-tolerated, the therapeutic benefits at these ultra-high doses as a monotherapy were mixed and less consistent. > **Key Takeaway:** The scientific consensus indicates that the optimal therapeutic window for CBD's antipsychotic properties sits between **800 mg and 1,000 mg per day**. Clinical trials consistently show that CBD at these doses is exceptionally well-tolerated, with a side-effect profile comparable to a placebo, primarily causing mild sedation or gastrointestinal changes. >
--------------------
Edited by JonBongGroovy (09/07/26 01:00 AM)
|